Pending — not yet graded
“Carnelian maintains large, untrimmed positions in pharma and CDMOs, viewing CDMOs as a robust long-term manufacturing theme. Biosimilars present a significant opportunity over the next five to seven years, while the broader pharma sector serves as a defensive anchor now and a growth story later.”
Vikas Khemani’s track record: 5 graded calls · 95% CI 38–96%
Nifty PharmaBullishCalled 24 Mar 2026
This call hasn't reached its evaluation window yet — the HIT/MISS verdict will appear here once it's graded against real price data. Save it above to find it again from your profile.
Read the original articleSee Vikas Khemani’s full track record